CASTLE BIOSCIENCES, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
CASTLE BIOSCIENCES, INC. (CSTL) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $0.00 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-07-30
- CASTLE BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $0.00.
- CASTLE BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.00.
- CASTLE BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- CASTLE BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $27.21, a 25.84% decline year-over-year.
- CASTLE BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- CASTLE BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $71.22, a 184.20% increase from fiscal 2023.
- CASTLE BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $25.06, a 12.13% increase from fiscal 2022.
- CASTLE BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $22.35, a 54.36% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-07-30 | |||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-03 | |||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-04 | |||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-05 | |||
| 2024-12-31 | $71.22 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $71.22 10-Q · filed 2024-11-04 | |||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-05 | |||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-02 | |||
| 2023-12-31 | $25.06 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $25.06 10-Q · filed 2023-11-02 | |||
| 2023-06-30 | $25.06 10-Q · filed 2023-08-02 | |||
| 2023-03-31 | $27.21 10-Q · filed 2023-05-03 | |||
| 2022-12-31 | $22.35 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $22.35 10-Q · filed 2022-11-02 | |||
| 2022-06-30 | $22.02 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $36.69 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $48.97 10-K · filed 2023-02-28 | |||
| 2021-09-30 | $67.79 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | $69.02 10-Q · filed 2021-08-09 | |||
| 2021-03-31 | $75.44 10-Q · filed 2021-05-10 | |||
| 2020-12-31 | $49.63 10-K · filed 2022-02-28 | |||
| 2020-09-30 | $38.93 10-Q · filed 2020-11-09 | |||
| 2020-06-30 | $33.04 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | $31.05 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | $19.41 10-K · filed 2021-03-11 | |||
| 2019-09-30 | $6.82 10-Q · filed 2019-11-12 | |||
| 2018-12-31 | $2.39 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B |